



**RETURN RESPONSES TO:
RETOURNER LES RÉPONSES À :**

Attention: **Denise Desserud**
Email | courriel: denise.desserud@canada.ca

**Request For Information
Demande de renseignement**

Comments – Commentaires:

Instructions: **See Herein**
Instructions: **Voir aux présentes**

Issuing Office – Bureau de distribution

Public Safety Canada
Contracting and Procurement Section
269 Laurier Avenue West
Ottawa ON K1A 0P8

Sécurité publique Canada
Section des contrats et approvisionnement
269, avenue Laurier ouest
Ottawa (ON) K1A 0P8

Title – Sujet Request for Information and Industry Engagement Activity on Roadside Oral-fluid Screening Devices	
Solicitation No. – No de l’invitation 20180ROFSD	Date 2018-04-09
Solicitation Closes – L’invitation prend fin At – à 2:00 p.m. On – le 2018-04-27	Time Zone Fuseau horaire Eastern Standard Time (EST)
Delivery Required – Livraison exigée See Herein	
Address Enquiries to: - Adresser toutes questions à: Denise Desserud	
Telephone No. – No de telephone (613) 990-2614	FAX No. – No de FAX (613) 954-1871
Destination – of Goods, Services and Construction: Destination – des biens, services et construction: Public Safety Canada 269 Laurier Avenue West, Ottawa ON K1A 0P8	
Security – Sécurité There is no security requirement associated with this requirement.	
Vendor/Firm Name and Address Raison sociale et adresse du fournisseur/de l’entrepreneur _____ _____ _____	
Telephone No. – No de telephone: _____	
Facsimile No. – No de télécopieur : _____	
Name and title of person authorized to sign on behalf of Vendor/Firm (type or print) Nom et titre de la personne autorisée à signer au nom due fournisseur/ de l’entrepreneur (taper ou écrire en caractères d’imprimerie) _____	
Signature	Date



Notice to suppliers—Request For Information and Industry Engagement Activity on Roadside Oral-fluid Screening Devices

April 9, 2018 — Ottawa— Public Safety Canada is releasing a Request For Information (RFI) and Industry Engagement Activity soliciting industry perspectives on submitting drug screening equipment (oral-fluid screening devices) for testing and potential participation in future solicitation process(s) for the purchase of the devices by Provinces and Territories as well as the Government of Canada in support of new proposed legislation with respect to drug-impaired driving, which complements proposed legislation concerning the implementation of the legalization of cannabis in Canada.

Background

The Government of Canada has engaged diverse stakeholders on the legalization of cannabis in Canada. In addition, the law enforcement community has been engaged on the enforcement of potential new offences, including potential new drug-impaired driving offences.

In support of this activity, Public Safety Canada is releasing this RFI, soliciting industry perspectives on timing and availability of Roadside Oral-fluid Screening Devices.

Respondents are invited to answer in writing the RFI questions and provide their comments, suggestions, and concerns and, where applicable, alternative recommendations regarding how the objectives or the outcomes described in this RFI could be satisfied.

Participation in this RFI is encouraged, but is not mandatory. There will be no short-listing of potential suppliers for the purposes of undertaking any future work as a result of this RFI. Similarly, participation in this RFI is not a condition or prerequisite for the participation in any potential subsequent solicitation.

Industry Engagement Activity

As part of this RFI process Canada would like to offer a presentation on the expected role of drug screening equipment in the criminal impaired driving framework and provide potential suppliers the opportunity to explain and express their comment(s) on the attached document. Should the interest arise from Industry, Canada will be hosting One-on-One meetings to be arranged with each interested manufacturer who has submitted information for consideration by the Drugs and Driving Committee (DDC) of the Canadian Society of Forensic Science under section 3 of the Oral Fluid Standards and Evaluation Procedures posted on their website at <https://www.csfs.ca/wp-content/uploads/2017/11/Approval-Standards-for-Drug-Screening-Equipment.pdf>.

Manufacturers interested in attending One-on-One meetings should do so by informing the Contracting Authority at least 48 hours prior to **April 13, 2019**.



Respondents will not be reimbursed for any cost incurred by participating in this Industry Engagement Activity and RFI.

Closing date for the RFI

Responses to this RFI must be submitted electronically to the Contracting Authority and will be accepted until 2:00 PM Eastern Standard Time (EST) **on April 27, 2018**. The information received after that date will be considered only to the extent reasonable, in the sole opinion of Canada.

Documents may be submitted in either official language of Canada.

PLEASE NOTE:

- The issuance of the RFI does not create an obligation for Canada to issue a subsequent bid solicitation.
- The RFI is not a bid solicitation and does not constitute a commitment, implied or otherwise, that the Government of Canada will take procurement action in this matter.
- Canada reserves the right to amend, delete or add, in whole or in part, any terms or provisions of this RFI document. Any revision will be provided in writing.
- No payment will be made for costs incurred in the preparation and submission of a response to the RFI and Industry Engagement Activities.
- Canada will have the right to accept or reject any or all recommendations

Enquiries

Any questions from respondents concerning this RFI must be made in writing to the Contracting Authority stated below, via e-mail on or before the closing date.

Denise Desserud
Senior Procurement Advisor
Public Safety Canada
269 Laurier
Email: denise.desserud@canada.ca
Phone: 613 990-2614



Questions

Question no 1:

If your device is selected for laboratory testing, how quickly could the device be sent to the laboratory to be tested?

Question no 2:

Should your device be selected as a listed device, how long would it take to manufacture 500, 1,000, 2,000 or 3,000 devices? We are looking for a timeline with respect to supplying the demand for 2018 and the next four years.

Question no 3:

Does your company have set pricing for devices and swabs? If so, can we obtain information about a price range? Would there be economies of scale if more devices were purchased at the same time? If so, please provide information.

Question no 4:

Do you foresee any challenges with the commercialization and distribution of your device(s)? If so, please describe them and any mitigation measures proposed.

Question no 5:

How soon would you expect to come out with another version of your device (a more advanced model)? Would this render the current model effectively obsolete or could it be retrofitted? Would there be an option to trade in the old device as credit towards a new one?